I-Mab (NASDAQ:IMAB – Get Free Report) and Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 22.6% of I-Mab shares are […]
/PRNewswire/ Hormone Replacement Therapy Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis Read.
SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics,. | May 31, 2022